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A B S T R A C T
Background: Acute Heart Failure (AHF) is a common cause of hospitalization in many 
countries. Rehospitalization due to AHF is also a very important economic issue for 
health services. Registries for AHF have been made in many countries to characterize 
such patients, which have provided great information about these patients for better 
care. To date, there is insufficient information about these patients in Iran and their 
rehospitalization and short- and long-term follow-up is unclear.
Objectives: This study aims to describe the results of a small registry of AHF (HFrEF) 
patients in Iran and their short-term follow-up.
Patients and Methods: This study aimed to describe the earliest results of the AHF 
registry, which was started from September 2015 in two hospitals (Afshar Heart Center 
in Yazd and Rajaie Heart Center in Tehran). All patients with diagnosis of AHF and 
HFrEF were enrolled into this registry. During six months, 352 patients with diagnosis of 
AHF and HFrEF were entered into this registry. The patients’ demographic, clinical, and 
Para clinical data were collected during hospitalization and they were followed up for 
all-cause mortality and hospitalization for three months. Patients suffering from heart 
failure with preserved ejection fraction were excluded because of their small number and 
incomplete data.
Results: The mean age of the patients was 55 ± 16 years and 76% were male. Besides, 77% 
of the patients had acute decompensation of chronic heart failure and 17% had new-
onset AHF. Etiology of heart failure was ischemic heart disease in 52% of the patients. 
Additionally, the mean left ventricular ejection fraction was 20%. Moreover, length of 
hospital stay was 10.5±10 days and in-hospital mortality rate was 9.7%.
Conclusions: This small and limited registry of patients with AHF (HFrEF) in Iran 
delineated these patients’ characteristics with some discrepancies and similarities with 
western registries. Thus, a larger nationwide registry is needed for further clarification 
of the issue.
*Corresponding author: Mohammad Hossein Soltani, Afshar Hospital, 
Gomhouri Boulevard, Yazd, Iran, Tel: +98-3535264320, 
E-mail: mhsoltane@gmail.com.
1. Background
Heart Failure (HF) is a major cause of morbidity and 
mortality worldwide, which significantly reduces life 
quality and longevity and increases healthcare costs (1-
3). There are multiple large registries for Acute Heart 
Failure (AHF) in western and industrialized countries (4-
9). However, there is limited published information about 
epidemiology and outcomes of patients with HF in Iran. 
The ADHERE registry in the U.S. is the largest registry 
of AHF in the world that has provided great information 
about these patents (4). These registries aim at evaluation 
of information about patients’ demographic data, hospital 
course, in-hospital mortality, and rehospitalization and 
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assessment of the relationship between mortality and 
rehospitalization and other variables.
Generally, there are some differences between Iranian 
people and those in developed countries regarding lifestyle, 
nutrition, and economic issues. Thus, studies have to be 
performed on the issue to identify similarities with and 
differences from other studies in this field. These differences 
provide information about how clinical guidelines from 
Western countries are used in Iran and whether these 
guidelines can be applied to Iranian patients.
2. Objectives
This study aims to clarify the patients’ characteristics and 
outcomes in Iran, identify similarities and differences in 
comparison to other studies, and point out some prognostic 
factors.
3. Patients and Methods
Rajaie and Afshar HF registry is a prospective observational 
cohort study, which was started in Rajaie Heart Center and 
Afshar Heart Center, Iran from September 2015 and is 
currently under way in these centers. Rajaie Heart Center 
located in Tehran, the capital of Iran, is a referral and tertiary 
hospital for patients with heart diseases. Afshar Heart Center 
is also located in Yazd, a city in center of Iran.
The current study aimed to describe the patients with AHF 
who were hospitalized in these centers for six months and 
were followed up for death and rehospitalization for three 
months. The proposal was accepted by these two centers 
and the study was conducted by fellowships of HF. This 
study was approved by the local Ethics Committee of Yazd 
Shahid Sadoughi University of Medical Sciences (Ethics 
Committee No. IR.SSU.REC.134871). Indeed, informed 
consents were obtained from all patients.
All adult patients (age ≥ 18 years) with diagnosis of AHF 
and reduced Left Ventricular Ejection Fraction (LVEF) who 
were hospitalized in the two above-mentioned centers were 
included in this study. AHF was diagnosed based on typical 
symptoms (dyspnea, edema, and fatigue), typical signs 
(elevated JVP, S3, cardiomegaly, and pulmonary crackles), 
and abnormal cardiac function in echocardiography (1). All 
patients had dyspnea at rest or with minimal activity and/or 
severe generalized edema accompanied with severe systolic 
HF (LVEF < 40%). Patients with acute coronary syndrome 
and cardiogenic shock were excluded because their data 
were not available. Patients with HFpEF were also excluded 
due to their small number. Patients who only suffered from 
right heart failure were excluded, as well.
All included patients underwent clinical evaluation, 
complete laboratory examination, and echocardiography 
by experienced cardiologists. In addition, their baseline 
information regarding demographics, medical history, and 
physical examination was collected at the time of admission.
Diabetes was defined as a previous diagnosis of this 
condition and was categorized as requiring insulin, oral 
hypoglycemic agent, and diet control. Besides, hypertension 
was defined as the previous history of this disease or current 
or previous use of antihypertensive drugs. Patients with 
the history of myocardial infarction, significant stenosis 
in at least one major coronary artery, and history of 
coronary revascularization were categorized as ischemic 
cardiomyopathy. Moreover, edema was defined severe 
if it was present over both legs and had deformed them. 
Worsening Renal Function (WRF) was defined as a ≥ 
0.3 mg/dL increase in serum creatinine in at least two 
samples during the index hospitalization up to discharge 
from hospital. It should be noted that serum creatinine level 
was measured every day. Anemia was defined according 
to the criteria suggested by World Health Organization 
(WHO); i.e., Hb < 13 g/dL in men and < 12 g/dL in 
women18. Furthermore, hyponatremia was defined as Na+ 
< 135 mmol/l. Echocardiography was done for all patients 
on the first day of admission and all data were gathered 
according to American Society of Echocardiography 
(ASE) guidelines. All-cause mortality during the initial 
hospitalization was recorded, as well. All patients were 
followed up for three months through telephone and 
mortalities or hospitalizations were recorded.
3.1. Statistical Analysis
Continuous variables were presented as mean ± standard 
deviation and categorical ones as frequency (percentage). 
Predictors of in-hospital mortality were firstly assessed by 
univariate analysis using binary logistic regression and 
Enter model. Then, all variables with p-values less than 
0.2 were entered into multiple logistic regression analysis 
(backward model). Additionally, three-month survival was 
derived using Kaplan-Meier method. All analyses were 
performed using the SPSS statistical software, version 16.
4. Results
This study was performed on 352 patients with AHF 
(233 patients from Rajaie Heart Center and 119 patients 
from Afshar Heart Center) with the mean age of 55 ± 16 
years. Totally, 76% of the patients were male and 77% had 
previous history of HF. The patients’ characteristics have 
been summarized in Table 1. According to the results, 
90% of the patients were NYHA class III or IV and 23% 
had severe generalized edema. Signs and symptoms of 
the patients have been shown in Table 2. The mean LVEF 
was 20 ± 6% and 23% of the patients had concomitant 
severe systolic right ventricular dysfunction. Moreover, 
the most common presentation was acute decompensation 
of chronic HF (77%) followed by acute de novo HF (18%), 
acute pulmonary edema (4%), and cardiogenic shock (1%). 
Drugs used during hospitalization and some laboratory data 
have been listed in Tables 3 and 4, respectively.
Length of hospital stay was 10.5 ± 10 days and in-hospital 
mortality rate was 9.7%. The results of univariate analysis 
indicated that systolic blood pressure < 90 mmHg (P = 0.007), 
admission BUN ≥ 50 mg/dL (P = 0.010), and WRF during 
hospitalization (P = 0.001) were significantly associated 
with higher in-hospital mortality. However, no significant 
association was found between in-hospital mortality and age, 
gender, etiology of ischemic HF, LVEF, cardiomegaly, and 
anemia. The results of multiple logistic regression analysis 
(backward model) showed a significant association between 
in-hospital mortality and systolic blood pressure < 90 mmHg 
(OR = 4.48 (95% CI: 1.21 - 16.55), P = 0.024) and WRF (OR 
= 9.33 (95% CI: 1.99 - 43.56), P = 0.004).
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Table 1. Characteristics of All Patients with AHF
Patients’ Characteristics Total (n = 352)
Age (years, SD) 55 ± 16
Male, n (%) 267(76)
Ischemic cardiomyopathy, n (%) 183(52)
Comorbidities
Diabetes, n (%) 131(37)
Hypertension, n (%) 94(27)
Smoking, n (%) 98(28)
Dyslipidemia, n (%) 125 (36)
COPD, n (%) 40(11)
Previous MI, n (%) 85(27)
Hypothyroidism, n (%) 28(8)
Hyperthyroidism, n (%) 2(.5)
ECG and chest X ray
Atrial Fibrillation, % 22
LBBB, % 19
Cardiomegaly, % 74
Pleural Effusion, % 14
Previous intervention
ICD, % 12
CRT,% 2.8
PCI, % 15
CABG, % 24
Predisposing factors
Pneumonia, % 7
Arrhythmia, % 15
Non-compliant with drugs, % 22
Acute coronary syndrome 22
In hospital death, n (%) 34(9.7)
Length of hospital stay, mean days (SD) 10.5 ± 10
Abbreviations: LBBB, left bundle branch block; ICD, implantable 
cardioverter defibrillator; CRT, cardiac resynchronized therapy; 
PCI, percutaneous coronary intervention; CABG, coronary 
artery bypass graft
Table 2. Frequency of Symptoms and Signs in Patients with 
AHF
Signs and Symptoms Frequency (%)
Dyspnea 98%
Orthopnea 67%
PND 47%
Fatigue 63%
Elevated JVP 88%
HeartS3 23%
Systolic murmur 47%
Rales 46%
Mild to moderate edema 73%
Severe edema 23%
Ascites 19%
Systolic BP, mm/Hg (mean, SD) 115 ± 24
Diastolic BP, mm/Hg (mean, SD) 74 ± 16
Heart rate (mean, SD) 87 ± 20
Respiratory rate (mean, SD) 18 ± 4
Abbreviation: PND, paroxysmal nocturnal dyspnea; JVP, jugular 
venous pressure
After three months, 84% of the patients were followed up 
by telephone and the remainders were lost to follow-up. The 
three-month survival curve has been depicted in Figure 1. 
During this period, 30% of the patients were readmitted 
due to worsening HF and 8.2% died. The total mortality 
rate (in-hospital and after discharge) was 20%.
Table 3. Pharmacotherapy of Patients during Hospitalization
Drugs Used in Patients Frequency
Beta blockers, % 83
ACEI or ARB, % 85
Spironolactone, % 72
IV Furosemide, % 88
Total daily furosemide dose, mg 158 ± 55
Metolazone, % 20
Digoxin, % 34
Warfarin, % 23
Atorvastatin, % 38
Amiodarone ,% 13
Aspirin or clopidogrel, % 40
Hydralazine, % 20
Parenteral Iron therapy, % 16
IV vasodilator, % 11
Inotropes, % 22
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; 
ARB, angiotensin receptor antagonist
Table 4. Laboratory Data of AHF Patients
Laboratory Variables Mean ± SD
Hemoglobin, mg/dL 12.9(2)
Creatinine at admission, mg/dL 1.34(0.7)
BUN at admission, mg/dL 30(20)
Na+, mmol/L 136(5)
NT-proBNP, mean pg/mL 6669
BNP, mean pg/mL 1220
Uric acid, mg/dL 7.6(2)
HbA1c, mg/dL 6.7(1.7)
Anemia, proportion (%) 43.9
Hyponatremia, proportion (%) 31
Figure 1. Kaplan-Meier Survival Analysis for Death during the 
Three-Month Follow-up
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5. Discussion
This study was the first report of an AHF registry in Iran, 
a two-center database that was primarily used to define 
the patients’ clinical and Para clinical characteristics and 
determine some prognostic factors. It should be mentioned 
that these centers are referral and tertiary ones for patients 
with heart diseases.
The mean age of our patients was 55 ± 16 years, which 
is obviously different from registries done in the U.S., 
European countries, Korea, and Japan (4-9). In these 
large registries from developed countries, the mean age 
of patients was around 70 years. This difference might 
be due to exclusion of HFpEF patients from the present 
study. It might also reflect the true difference between our 
population and those from developed countries. In one 
study performed on AHF patients in Saudi Arabia (10), 
the mean age was 60 years. Another study in India (11) 
also revealed that patients’ mean age was 61 years. One 
other study in Africa (12), too, reported the mean age to 
be 52 years, which is close to that reported in the current 
study. This also supports the true difference between our 
population and those from developed countries. Moreover, 
the mean age of Iranian patients with acute myocardial 
infarction was about 62 years (13, 14), which is lower 
compared to developed countries. This might be due to 
the HF patients’ lower age.
In HF registers from developed countries, about 40 - 50% 
of patients with HF suffered from HFpEF (4, 7). However, 
the number of patients with HFpEF was very low in our 
registry and, consequently, their data were excluded from 
analysis. This low frequency of HFpEF patients could 
be attributed to registration of patients from two heart 
hospitals. These patents are normally old and hospitalized 
in general hospitals. Thus, finding and registration of these 
patients requires cooperation among many hospitals. From 
another point of view, the low frequency of HFpEF patients 
might be due to the younger population of Iran. This is 
supported by lower prevalence of HFpEF in registries from 
Africa (12) and Asia (10, 11) in comparison to those from 
developed countries.
The number of female patients was low in the present 
study, which could result from the low number of HFpEF 
patients who are usually old female ones.
The etiology of HF was ischemic heart disease in nearly 
half of the patients, which is comparable with many other 
studies conducted on the issue (4, 7).
 Hypertension as a major risk factor for HF was seen only 
in 27% of the current study patients, which is considerably 
lower than 50 - 57% reported in large western registries 
(4, 7). Our patients were significantly young, suffered 
from severe systolic dysfunction, and did not have 
HFpEF. Hypertension is seen less in these populations. In 
OPTIMIZE registry also, hypertension was less frequent 
in systolic HF in comparison to HFpEF (15).
Elevated Jugular Venous Pressure (JVP) was the most 
common sign in the present study patients (88%). However, 
it was reported in only 33% of patients in OPTIMIZE 
registry (15). Our patients were examined and treated by 
fellowships of HF. It seems that careful examination might 
increase the positivity of this important sign. On the other 
hand, Left Bundle Branch Block (LBBB) was seen in 19% 
of our patients and all these patients’ LVEF was < 30%. 
Nonetheless, implantation of Implantable Cardioverter 
Defibrillator (ICD) and Cardiac Resynchronization 
Therapy (CRT) were done in minority of the patients. This 
is mostly due to financial issues and lack of such devices 
in our country.
In the current study, thyroid disease was detected in 10% of 
the patients. This disease may affect the course of treatment, 
which indicates the necessity of thyroid evaluation in 
all patients with advanced systolic HF. The results also 
revealed a relationship between thyroid dysfunction and 
WRF, which was noted by Merla, as well (16).
In the current study, evidence-based drugs like beta 
blockers, Angiotensin Converting Enzyme Inhibitor 
(ACEI), Angiotensin Receptor Antagonist (ARB), and 
Mineralocorticoid Receptor Antagonist (MRA) were used 
in the majority of patients. Use of Inotrope was also similar 
to other studies conducted on the issue (5, 8, 10).
In the present study, the rate of in-hospital mortality was 
10%. This measure varied from 4% to 13% in the previous 
studies (4, 10, 17), which could be attributed to differences in 
design and population of studies. Among multiple interactive 
variables that had a significant association with in-hospital 
mortality in univariate analysis, systolic blood pressure < 
90 mmHg and WRF had a significant impact on in-hospital 
mortality in multivariate analysis. In OPTIMIZE registry, 
older age and lower systolic blood pressure were significant 
predictors of in-hospital mortality (15).
Echocardiographic study in our patients showed no 
significant association between LVEF and in-hospital 
mortality. It seems that LVEF is not a reliable predictor of 
poor outcomes in advanced systolic HF, which needs to be 
explored in future studies.
In the present study, WRF during hospitalization was 
found in 40% of the patients. Indeed, it had a significant 
impact on in-hospital mortality and 3-month survival, 
which is consistent with the results of some other studies 
(18-20).
Anemia was also detected in 44% of the patients, but it had 
no prognostic importance in this study. However, several 
other studies have referred to its prognostic importance (21, 
22). The difference between the results could be possibly 
due to the small population of our study.
The present study has some strengths and limitations. 
This study was performed on a prospective registry and all 
patients were examined and treated under supervision of HF 
specialists in a heart center. This might cause less variability 
in the data. On the other hand, the results of a two-center 
study on a special population cannot be generalized to the 
entire community. Indeed, we did not have access to all 
medical options and left ventricular assist devices, which 
could affect the medial course and mortality.
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